Lunit vs Qure.ai
Qure.ai holds ten FDA 510(k) records to Lunit's six, and the chest X-ray entries differ. Lunit's chest X-ray record is INSIGHT CXR Triage, cleared in 2021. Qure's qXR-LN (K231805) was cleared in December 2023 for radiologists, pulmonologists and ER physicians reading adult frontal chest radiographs, and qXR-PTX-PE adds pneumothorax and effusion triage. Qure also reads head CT with qER. Lunit's other records cover 2D mammography and tomosynthesis, with Volpara tools for density, so a breast imaging center that also reads chest films buys from Lunit. A US hospital shopping for nodule detection on radiographs finds Lunit gives way to Qure. On TB, an independent PLOS Digital Health comparison found a newer INSIGHT CXR version less accurate until its threshold was recalibrated, while an independent 12-product evaluation put qXR v3 at 95.5% sensitivity with 48.7% specificity at one threshold.
Radiology · Reviewed November 2, 2026
When to pick each one
Lunit
- Volpara density tools alongside mammography AI
- INSIGHT CXR Triage, 510(k) cleared in 2021
- Lunit says WHO recommended it for TB screening
Qure.ai
- qXR-LN nodule detection on adult frontal chest radiographs
- qXR-PTX-PE pneumothorax and effusion triage, 2023
- 10 FDA records on openFDA across chest and CT
Score
Each row shows points earned of points available under the published rubric.
Lunit
66of 100
Qure.ai
50of 100
| Dimension | Lunit | Qure.ai | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 12.7 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 0 / 7.8 | +7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Lunit
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Qure.ai
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Grant funding is not stated on Qure pages. |
Evidence
Lunit
FDA decisions
K260320 (opens in new tab)510(k)2026-04-23
Lunit INSIGHT MMG (v1.1.10)
K253796 (opens in new tab)510(k)2026-03-26
Lunit INSIGHT DBT (V1.2)
K242652 (opens in new tab)510(k)2024-10-04
Lunit INSIGHT DBT v1.1
K231470 (opens in new tab)510(k)2023-11-06
Lunit INSIGHT DBT
K211678 (opens in new tab)510(k)2021-11-17
Lunit INSIGHT MMG
Show 3 more
K211733 (opens in new tab)510(k)2021-11-10
Lunit INSIGHT CXR Triage
K211279 (opens in new tab)510(k)2021-07-27
Volpara Imaging Software
K182310 (opens in new tab)510(k)2018-09-21
Volpara Imaging Software
Peer-reviewed
3 PubMed records name Lunit.
- Comparison of different Lunit INSIGHT CXR software versions when reading chest radiographs for tuberculosis. (opens in new tab)
- Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). (opens in new tab)
- Long-term prognostic implications of AI-detected versus AI-undetected breast cancers on mammography: a propensity score-matched analysis. (opens in new tab)
Qure.ai
FDA decisions
K261517 (opens in new tab)510(k)2026-09-14
qCT Lung v1.0
K251934 (opens in new tab)510(k)2026-01-16
qXR-Detect
K251610 (opens in new tab)510(k)2025-09-08
qER-CTA v1.0
K240740 (opens in new tab)510(k)2024-08-16
qCT LN Quant
K231805 (opens in new tab)510(k)2023-12-22
qXR-LN
Show 5 more
K231149 (opens in new tab)510(k)2023-09-22
qXR-CTR
K230899 (opens in new tab)510(k)2023-08-22
qXR-PTX-PE
K212690 (opens in new tab)510(k)2021-12-21
qXR-BT
K211222 (opens in new tab)510(k)2021-07-30
qER-Quant
K200921 (opens in new tab)510(k)2020-06-17
qER
Peer-reviewed
4 PubMed records name Qure.ai.
- Radiograph accelerated detection and identification of cancer in the lung (RADICAL): a mixed methods study to assess the clinical effectiveness and acceptability of Qure.ai artificial intelligence software to prioritise chest X-ray (CXR) interpretation. (opens in new tab)
- Revolutionizing Healthcare: Qure.AI's Innovations in Medical Diagnosis and Treatment. (opens in new tab)
- A Case Series From a Multicentric Study: Can Artificial Intelligence (AI)-Enabled Chest X-Ray Assist in the Incidental Detection of Early-Stage Lung Cancers? (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Lunit | Qure.ai |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2013 | n/a |
| HQ | KR | IN |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.


